Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

By S. Adams, R. Gray, S. Demaria, L. Goldstein, E. Perez, L. Shulman, S. Martino, Molin Wang, V. Jones, T. Saphner and 6 more. Journal of Clinical Oncology, 2014

1,170 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a358d851356e7fb3dae161444160a1faab167822

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Garrido-Castro
2. K. Polyak
3. S. Demaria
4. H. Moses

In Oncology

1. K. Polyak
2. J. Reis-Filho
3. A. Garrido-Castro
4. A. Richardson
5. David L. Rimm
6. S. Demaria
7. J. Brock
8. H. Moses

Citations in the corpus

• Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “Analyses from neoadjuvant and adjuvant TNBC trials have shown that tumor-infiltrating lymphocytes (TIL), assessed by hematoxylin–eosin staining, are predictive of response to therapy and strongly associated with improved survival (107, 108).”
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015, methodology): “This correlation was first reported using baseline samples from the BIG 2–98 trial [22] and subsequently independently confirmed in 481 TNBC sample prospectively collected during two phase III adjuvant randomized BC trials [United States Eastern Cooperative Oncology Group (ECOG) trials 2197 and 1199”
• Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study (2019, neutral): “(%) [95% CI] 5 (24) [8-47] 10 (11) [5-19] 0 [0-17] 15 (16) [10-26]”
• The impact of pre- and post-image processing techniques on deep learning frameworks: A comprehensive review for digital pathology image analysis (2020, background): “…of lymphocyte presence in cancer can potentially allow for the design of new biomarkers to help monitor the rapid progression of a tumor [147], as recent studies have shown how the lymphocytes can serve as a fundamental biomarker to predict clinical outcomes and treatment response [148,149].”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, neutral): “…highly proliferative breast cancers, and have been associated with increased pCR, longer disease-free survival (DFS), and improved overall survival (OS), independent of other prognostic factors [53, 54] in some studies, though not among patients treated with trastuzumab in the N9831 trial [55].”
• Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (2016, positive): “Of note, recent studies have shown that the presence of TILs are associated with better response to adjuvant chemotherapy[32] and neoadjuvant chemotherapy[23].”